Oto vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 38)
Oto logo

Oto

EmergingHealthcare

General

London digital CBT app for tinnitus with DEFINE Trial evidence showing 86% benefit in one month; £2.8M seed competing with Widex and ReSound for 750M global tinnitus sufferers needing accessible specialist care.

AI VisibilityBeta
Overall Score
D38
Category Rank
#454 of 596
AI Consensus
85%
Trend
stable
Per Platform
ChatGPT
36
Perplexity
33
Gemini
40

About

Oto is a London-based digital health company providing clinically validated, app-based CBT (cognitive behavioral therapy) treatment for tinnitus — the persistent ringing, buzzing, or hissing in the ears that affects 15% of the global population (750 million+ people) with no pharmaceutical cure — delivering structured therapeutic programs designed by tinnitus specialists that help patients manage and reduce tinnitus distress through evidence-based psychological and sound therapy techniques. Founded and backed with £2.8 million in seed funding raised in 2022, Oto demonstrated in the DEFINE Trial (the largest randomized controlled trial for any digital tinnitus program) that 86% of users experience measurable benefits within one month of the program.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

38
Overall Score
90
#454
Category Rank
#2
85
AI Consensus
83
stable
Trend
stable
36
ChatGPT
92
33
Perplexity
93
40
Gemini
89
36
Claude
96
37
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.